Technical Analysis for INVA - Innoviva, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 11.89 | -0.08% | -0.01 |
Earnings due: Apr 27
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Flat | Flat | Flat |
| Historical INVA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 200 DMA Support | Bullish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| 20 DMA Resistance | Bearish | -0.08% | |
| 200 DMA Support | Bullish | -0.08% | |
| Crossed Above 50 DMA | Bullish | -0.08% | |
| Up 3 Days in a Row | Strength | -0.08% | |
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 50 DMA Support | about 11 hours ago |
| 200 DMA Support | about 11 hours ago |
| 10 DMA Support | about 11 hours ago |
| Rose Above 10 DMA | about 11 hours ago |
| 20 DMA Resistance | about 11 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 04/27/2021
Innoviva, Inc. Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Drugs Asthma Pulmonary Disease Novi Chronic Obstructive Pulmonary Disease Icos Glucocorticoids Treatment Of Chronic Obstructive Pulmonary Disease Corticosteroid Organofluorides Antero Respiratory Products Fluticasone
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.62 |
| 52 Week Low | 9.21 |
| Average Volume | 502,200 |
| 200-Day Moving Average | 11.85 |
| 50-Day Moving Average | 11.88 |
| 20-Day Moving Average | 11.93 |
| 10-Day Moving Average | 11.89 |
| Average True Range | 0.36 |
| ADX | 14.83 |
| +DI | 22.49 |
| -DI | 21.57 |
| Chandelier Exit (Long, 3 ATRs ) | 11.79 |
| Chandelier Exit (Short, 3 ATRs ) | 12.46 |
| Upper Bollinger Band | 12.39 |
| Lower Bollinger Band | 11.47 |
| Percent B (%b) | 0.46 |
| BandWidth | 7.74 |
| MACD Line | -0.02 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0173 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.37 | ||||
| Resistance 3 (R3) | 12.34 | 12.14 | 12.29 | ||
| Resistance 2 (R2) | 12.14 | 12.02 | 12.16 | 12.26 | |
| Resistance 1 (R1) | 12.02 | 11.95 | 11.92 | 12.05 | 12.24 |
| Pivot Point | 11.82 | 11.82 | 11.78 | 11.84 | 11.82 |
| Support 1 (S1) | 11.70 | 11.70 | 11.60 | 11.73 | 11.54 |
| Support 2 (S2) | 11.50 | 11.63 | 11.52 | 11.52 | |
| Support 3 (S3) | 11.38 | 11.50 | 11.49 | ||
| Support 4 (S4) | 11.41 |
